The World Health Organization (WHO) recommends typhoid conjugate vaccine (TCV) for use in all typhoidendemic countries. TCV has several advantages compared to previously available typhoid vaccines including higher efficacy, longer-lasting protection, single dose administration, and suitability for children as young as six months old, allowing for delivery through routine childhood immunization programs.
685 West Baltimore Street, Room 480
Baltimore, MD 21201-1509
Baltimore, MD 21201-1509
Washington, DC 20006
© 2018. Coalition Against Typhoid. All Rights Reserved.